Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: JANX

Janux Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for JANX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.64

Janux Therapeutics, Inc. (NASDAQ: JANX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:51 UTC.

What Janux Therapeutics, Inc. does

Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies using three proprietary platforms: TRACTr, which produces T cell engagers with tumor antigen-binding and CD3 T cell binding domains; TRACIr, which produces bispecifics with tumor antigen-binding and costimulatory CD28 binding domains; and ARM, designed for controlled T cell activation in autoimmune diseases and oncology.

Summarized from Janux Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.64

Revenue, margins & earnings

FY2021: net loss $33M on revenue $4M$4MFY2021FY2022: net loss $63M on revenue $9M$9MFY2022FY2023: net loss $58M on revenue $8M$8MFY2023FY2024: net loss $69M on revenue $11M$11MFY2024FY2025: net loss $114M on revenue $10M$10MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-31
  • 2026-07-31President and CEOGift-123,840—
  • 2026-07-10President and CEOOption exercise7,000$29.5K
  • 2026-07-10President and CEOStock Option (right to buy)Option exercise-7,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Janux Therapeutics, Inc. do?

Janux Therapeutics, Inc. is a biotechnology company, listed on NASDAQ as JANX.

When did JANX last file with the SEC?

Janux Therapeutics, Inc.'s most recent SEC filing on record is a SCHEDULE 13G/A filed 2026-08-14. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 01:51 UTC. This page is also available as JSON at /api/data?ticker=JANX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for JANX and 5,000+ tickers.

Create a free account — keep JANX
For your agent
GET /api/data?ticker=JANX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt